HyperTET® S/D is indicated for prophylaxis against tetanus following injury in patients whose immunization is incomplete or uncertain.

It is also indicated, although evidence of effectiveness is limited, in the regimen of treatment of active cases of tetanus. A thorough attempt must be made to determine whether a patient has completed primary vaccination.

Patients with unknown or uncertain previous vaccination histories should be considered to have had no previous tetanus toxoid doses. Persons who had military service since 1941 can be considered to have received at least one dose, and although most of them may have not completed a primary series of tetanus toxoid, this cannot be assumed for each individual. Patients who have not completed a primary series may require tetanus toxoid and passive immunization at the time of the wound cleaning and debridement.

For indications, dosing and other information, please refer to the prescribing information.

HyperTET® ‐ Grifols

250 unit syringe
NDC #: